Evidence map›Paper›PMID 36422803›Full record

ArticleDiabetes therapy : research, treatment and education of diabetes and related disorders2023

STYLCONNECT Study: An Assessment of Automatic Data Collection Devices by People Living with Diabetes and Using an Insulin Pen.

Nicolas Naïditch, Christine Mauchant, Imane Benabbad, Coline Hehn, Michael Joubert, Jean-François Thébaut, Myriam Rosilio

Open access · goldAbstract read
In one paragraph

Article in Diabetes therapy : research, treatment and education of diabetes and related disorders, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.6field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Nicolas NaïditchFédération Française des Diabétiques [French Federation of Diabetics - FFD], Diabète LAB., 88 Rue de la Roquette, 75011, Paris, France. n.naiditch@federationdesdiabetiques.org.
Christine MauchantLilly France, Neuilly sur Seine, France.
Imane BenabbadLilly France, Neuilly sur Seine, France.
Coline HehnFédération Française des Diabétiques [French Federation of Diabetics - FFD], Diabète LAB., 88 Rue de la Roquette, 75011, Paris, France.
Michael JoubertService d'endocrinologie-Diabétologie [Endocrinology/Diabetes Unit], Centre Hospitalier Universitaire de Caen, Caen, France.
Jean-François ThébautFédération Française des Diabétiques [French Federation of Diabetics - FFD], Diabète LAB., 88 Rue de la Roquette, 75011, Paris, France.
Myriam RosilioLilly France, Neuilly sur Seine, France.
Hôpital américain de paris · FRCentre Hospitalier Universitaire de Caen · FRUniversité de Lorraine · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionThe use of devices to connect insulin pens could facilitate management and improve glycaemic control in people with type 1 (PwT1D) and type 2 diabetes (PwT2D). However, their acceptance seems little studied. We conducted an online survey with the main objective of assessing the level of interest among insulin-treated people with diabetes (PwD) in a device connected to a disposable pen and secondary objectives of assessing the perceived benefits and important features expected of a connected device and identifying factors associated with interest scores.

methodsAn ad-hoc questionnaire, validated by PwD, was used. Responses from 1798 PwD (975 PwT1D and 823 PwT2D) were analysed.

resultsThe mean interest rating was 7.4/10 (PwT1D: 7.2 vs PwT2D: 7.7; p < 0.001). PwD perceived that the device would make it easier to record their diabetes-related information (7.7/10) and keep all insulin and diabetes data in a single location (7.7/10). It was particularly important for PwD that this type of device could integrate data from glucose-measuring devices (7.8/10) and could set an alarm when all insulin in the body had been metabolised (7.7/10).

conclusionOur study highlighted PwD's strong interest in automating the collection of their insulin therapy data, with significantly more interest among PwT2D than PwT1D, and the importance of interoperability between glucose measurement devices and interchangeability between the different brands of insulin. More generally, for the first time and on a large scale, our study provided a greater understanding of the expectations of PwD regarding these devices.

Indexed as

Connected medicineConnected penDiabetes managementInsulinType 1 diabetesType 2 diabetes

Identifiers

PMID36422803
PMCPMC9944131
OpenAlexW4309896554

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.